Example of this RLT include severe manifestations attributed to pseudoprogression that do not improve with medical or surgical intervention. The number and percentage of patients experiencing RLTs will be summarized. Additionally, the number and percentage of patients experiencing each type of RLT corresponding to each of the criteria given above will be summarized. If a patient experiences more than one RLT of the same type, the patient will be counted only once under that category. Summaries of RLTs will be reported using the Treated Population. RLTs will be listed for all patients in the ITT Population. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 40 of 63 9.5. LABORATORY EVALUATIO NS Laboratory results collected in conventional units will be converted to Internationa l System of Units (SI) for all summaries and listings. A listing of all the relevant conversi on factors will be provided in the analysis dataset specifications. Clinical laboratory tests (hematology, chemistry, coagulation parameters, and u rinalysis) will be collected at Screening, at Day 1, and bi-weekly starting at Week 2 through Week 22 . Beyond week 22, lab data will be collected every 4 weeks (ie, while the patient remains on tre atment) as well as at the end of treatment. Clinical laboratory test results and their changes from baseline will b e summarized by visit using descriptive statistics. For hematology, serum chemistry and coagulation paramet ers, tests will be categorized as low, normal, or high based on their normal ranges. For urinalysis tes ts, results will be classified as normal or abnormal. The number and percentage of patients having abnormal values will be presented by study vi sit. Percentages will be based upon the number of patients who had measurements for that lab parameter at the study visit. Shift tables using categories of low, normal, and high, comparing laboratory test re sults from baseline to end of study will be presented with percentages based on the Trea ted Population for patients with a non-missing value at baseline and end of study. The lab parameters to be included in the summary tables are shown in Table 2.